Clinical trial NCT05353686: A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes
Official title: A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial Investigating the Effect of 4 Weeks Bi-daily Dosing of XEN-D0501 on Blood Glucose Reduction as add-on to Metformin in Patients With Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Efficacy
Safety
Pharmacokinetics
Diabetes Mellitus, Type 2
Lead sponsor: Pila Pharma
Sponsor class: INDUSTRY
Collaborators: name: Biomapas
First posted: 2022-04-29
Enrollment: 54
Sex: ALL
Minimum age (years): 25
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a 4 weeks randomised, double-blind, placebo-controlled, parallel-group, prospective trial. Each subject will be randomised to 1 out of 2 possible treatment arms and treated for four weeks.
Primary purpose: TREATMENT

Brief summary: This is a randomised, double-blind, placebo-controlled, parallel-group trial investigating the effect of 4 weeks bi-daily dosing of XEN-D0501 on blood glucose reduction as add-on to metformin in patients with diabetes mellitus type 2 where life style changes and treatment with metformin has failed to effectively reduce blood glucose concentrations.


Eligibility criteria: Inclusion Criteria:

1. The subject must give his/her signed and dated informed consent before any trial-related activities. Trial-related activities are any procedures that would not have been performed during the normal management of the subject
2. Diagnosis of type 2 diabetes mellitus
3. In treatment with a stable metformin dose during the last three months, but no other anti-diabetic drugs
4. HbA1C (glycosylated haemoglobin A1C): 6.5-10 %
5. Age above 25

Exclusion Criteria:

1. A subject with a history of significant multiple drug allergies or with a known or suspected allergy to the trial product or any medicine chemically related to the trial product, as judged by the Investigator.
2. A subject who has a clinically significant abnormal ECG at screening, as judged by the investigator.
3. A subject who has participated in any other trials involving investigational products within the 3 months preceding the start of dosing.
4. A subject who has donated any blood or plasma in the past month or in excess of 500 mL within 1 month preceding screening.
5. A subject who has a significant history of alcoholism or drug/chemical abuse as per investigator's judgement.
6. A subject with mental incapacity or language barriers which preclude adequate understanding or cooperation, who is unwilling to participate in the trial, or who in the opinion of their general practitioner or the Investigator should not participate in the trial.
7. Surgery or trauma with significant blood loss within the last 2 months prior to dosing.
8. A subject with a clinically significant abnormal haematology or biochemistry tests at screening visit, as judged by the Investigator considering the underlying disease.
9. Current treatment with drugs known to interfere with glucose metabolism such as systemic corticoids and monoamine oxidase inhibitors (MAO) inhibitors.
10. Haemoglobin \< 6.2 mmol/l (\<99.8 g/l), total leukocyte count \< 3.0 x 109/l, thrombocytes \<100 x 109/l, serum creatinine levels ≥ 126 μmol/l (male) or ≥ 111 μmol/l (female), bilirubin \> 3 x ULN, alanine aminotransferase \> 2 x the upper limit of normal (ULN), alkaline phosphatase \> 2 x ULN, one re-test within a week is permitted.
11. Previous participation (randomisation) in this trial.
12. Any condition that would interfere with trial participation or evaluation of results, as judged by the investigator and/or sponsor
13. Recurrent major hypoglycaemia or hypoglycaemic unawareness, as judged by the Investigator.
14. Females of childbearing potential (i. e. not post-menopausal ≥ 12 months or surgically sterilised) who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures include sterilisation, hormonal intrauterine devices, oral hormonal contraceptives (p-pills), implantants, transdermal patches, p-ring or depot injection, sexual abstinence or vasectomised partner). A male subject who is sexually active and has not been surgically sterilised must be informed that he must ensure that his partner practices effective contraception, as stated above, or he must refrain from sexual intercourse during the trial and until 90 days after completion of the trial. This is to prevent the possibility of a pregnancy from spermatocytes that can potentially be damaged by trial medication.

Primary outcomes:
measure: Primary endpoint
timeFrame: 4 weeks of treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Jonava
country: Lithuania
facility: Kristavita, JSC
city: Kaunas
country: Lithuania
facility: "Auki sveikas" ("A klinika")
city: Kaunas
country: Lithuania
facility: Saules seimos medicinos centras, JSC
city: Kaunas
country: Lithuania
facility: Kaunas City Polyclinic / Dainava Outpatient Clinic
city: Kedainiai
country: Lithuania
facility: Kedainiai Hospital / Outpatient Department
city: Klaipeda
country: Lithuania
facility: A. Navickas Outpatient Clinic
city: Vilnius
country: Lithuania
facility: Karoliniskiu Outpatient Clinic
city: Vilnius
country: Lithuania
facility: Vilnius University Hospital Santaros Clinics / Family Center Department
city: Vilnius
country: Lithuania
facility: Vilnius University Hospital Santaros Clinics
city: Vilnius
country: Lithuania
facility: Vaidotas Urbanavicius Sole Proprietary Enterprise
Study officials:
affiliation: Pila Pharma
name: Dorte X Gram, PhD
role: STUDY_DIRECTOR
References: